Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Early Phase 1 Trial to Assess Pharmacodynamic Effects of OMO-103 in Patients With Pancreatic Ductal Adenocarcinoma

NCT07089940 is registered in ClinicalTrials.gov with OHSU Knight Cancer Institute as lead sponsor.

NCT NCT07089940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07089940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Early Phase 1 Trial to Assess Pharmacodynamic Effects of OMO-103 in Patients With Pancreatic Ductal Adenocarcinoma
Lead sponsor
OHSU Knight Cancer Institute
Phase
Phase 1
Overall status
Recruiting
Start date
January 27, 2026
Completion date
December 31, 2027
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced pancreatic ductal adenocarcinoma, metastatic pancreatic ductal adenocarcinoma, stage ii pancreatic cancer ajcc v8, stage iii pancreatic cancer ajcc v8, stage iv pancreatic cancer ajcc v8